Burzynski Research (BZYR) 0.0700 $BZYR
Burzynski Research Institute, Inc. Announces the Launch of a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma
BusinessWire - Thu Apr 14, 10:32AM CDT
Burzynski Research Institute, Inc. (BRI) announced today that it has begun patient enrollment into an FDA-reviewed and IRB-approved, open-label, single-arm phase 2 study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (greater-than or equal to 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor).
Anaplastic Astrocytoma Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/mp9hzf/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Anaplastic Astrocytoma Overview - Therapeutics Development - Pipeline Products for Anaplastic Astrocytoma - Overview - Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis - Anaplastic Astrocytoma - Therapeutics under Development by Companies - Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes - Anaplastic Astrocytoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Anaplastic Astrocytoma - Products under Development by Companies - Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes - Anaplastic Astrocytoma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Amgen Inc. - Axelar AB - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - Celldex Therapeutics, Inc. - e-Therapeutics Plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/mp9hzf/anaplastic
ADRO: 14.68 (-0.24), PFE: 36.89 (+0.22), CLDX: 4.62 (-0.10), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), NVS: 83.26 (+1.18)
A Look at Four Brain Cancer Companies for 2016
ACCESSWIRE - Mon Jan 04, 10:34AM CST
NEW YORK, NY / ACCESSWIRE / January 4, 2016 / BioTechstocks.com - Brain tumors are among the most difficult to treat cancers in the oncology space. Their tendency for late stage diagnosis, and the difficulty associated with surgical treatment, translates to a higher than 65% mortality rate in the US, defined as the percentage of patients that die within five years of diagnosis. Choosing to pursue brain cancer treatment is risky for a company precisely because it is so hard to treat. That's why new approaches are being pursued mainly by smaller companies trying to make an impact with bigger risk-taking. Here are four candidates from these smaller firms to keep in eye in 2016.
DMPI: 6.58 (-0.32), VBLT: 4.02 (unch), IMUC: 0.19 (-0.01)
Burzynski Research Institute, Inc. Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1
BusinessWire - Mon Dec 07, 12:42PM CST
Burzynski Research Institute, Inc. (BRI) announced today the publication of "A Phase II Study of Antineoplastons A10 and AS2-1 (ANP) in Adult Patients with Primary Brain Tumors - Final Report (Protocol BT-09)". This single arm, two stage, phase II clinical trial, was designed to treat adults with different types of primary brain tumors that were not curable by standard therapy. Fourteen of 40 patients treated (35%) had an anaplastic glioma (AG), of which 12 (86%) had an anaplastic astrocytoma (AA), a grade 3 tumor with a poor prognosis. In BT-09, the objective response rate in AA patients was 42% while the median progression-free survival was 5.4 months. The median overall survival (OS) for AA patients was 25.4 months with the OS at 6 months, 1 year, and 2 years being 83%, 58%, and 50% respectively, which compares favorably with current standard treatment. ANP was well-tolerated with reversible grade 3 and 4 toxicity in 35% of all 40 patients treated. After a review of BRI's Investigator Brochure and annual reports, which documented outcomes for all AGs treated with ANP in phase II clinical trials, the FDA, in personal correspondence with BRI, advised an end-of-phase II meeting "for grade 3 AGs, specifically AA, anaplastic oligodendroglioma, and mixed oligoastrocytoma [OR rate of 20% (95% CI: 12, 31)]", indicating that ANP exhibited sufficient clinical activity in these tumors to justify further development.
Burzynski Research Institute, Inc. Announces Publications Documenting Long-term Survival in Malignant Brain Tumors Following Antineoplaston Therapy
PR Newswire - Mon Oct 26, 5:03PM CDT
Burzynski Research Institute, Inc. (BRI) announced today the publication of two articles in the peer-reviewed literature that document long-term survival in patients with a high-grade glioma (HGG) following Antineoplaston therapy (ANP). Following standard therapy, HGGs have a very poor prognosis. A meta-analysis of 575 HGG studies involving 42,332 patients showed median overall survival ranging from 9.89 to 15.45 months depending on the type of adjuvant chemotherapy employed [Leonard A, et al. J. Neuro Oncol 2012 Jun; 14(Suppl 1): 156-168. doi: 10.1093/neuonc/nos12].
Gliosarcoma Pipeline Review H1 2015 - Analysis of 7 Companies & 11 Drug Profiles
M2 - Tue Jul 28, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mmkt6/gliosarcoma) has announced the addition of the "Gliosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Burzynski Research Institute, Inc. - Celgene Corporation - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Sanofi Drug Profiles - alisertib - Antineoplaston Therapy - CC-122 - DNX-2401 - indoximod - lonafarnib - Oncolytic Virus to Target IL-12 for Oncology - plerixafor - rilotumumab - SGT-53 - Stem Cell Therapy for Glioma For more information visit http://www.researchandmarkets.com/research/5m...liosarcoma
MRK: 58.66 (+0.23), NLNK: 10.58 (-0.53), AMGN: 172.03 (+0.75), CELGZ: 1.16 (-0.01)
Anaplastic Astrocytoma - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv742d/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amgen Inc. - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - e-Therapeutics plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncovir, Inc. - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/cv742d/anaplastic
PFE: 36.89 (+0.22), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), NVS: 83.26 (+1.18)
Anaplastic Astrocytoma Therapeutic Products and Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 18, 8:30PM CDT
The report "Anaplastic Astrocytoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Anaplastic Astrocytoma with 33 market data tables and 14 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/anaplastic-a...eport.html .
PFE: 36.89 (+0.22), LLY: 82.89 (-0.04), NVS: 83.26 (+1.18)
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma
BusinessWire - Thu Jun 18, 2:09PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Patients with Non-Diffuse Intrinsic Pontine Glioma
BusinessWire - Thu Apr 16, 5:46PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain and brainstem tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma
BusinessWire - Tue Mar 31, 4:25PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with rare brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver
PR Newswire - Thu Mar 26, 5:51PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver.
Burzynski Research Institute awarded US FDA's approval to begin new clinical trial in Diffuse Intrinsic Brainstem Glioma
M2 - Mon Oct 27, 6:20AM CDT
Biopharmaceutical company Burzynski Research Institute (Other OTC:BZYR) revealed on Friday that it has received approval from the US Food and Drug Administration (FDA) to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > three months of age with a diffuse intrinsic brainstem glioma (DIPG), the most common brainstem tumor in children.
Burzynski Research Institute, Inc. Announces the Launch of a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma
BusinessWire - Thu Apr 14, 10:32AM CDT
Burzynski Research Institute, Inc. (BRI) announced today that it has begun patient enrollment into an FDA-reviewed and IRB-approved, open-label, single-arm phase 2 study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (greater-than or equal to 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor).
Anaplastic Astrocytoma Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/mp9hzf/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Anaplastic Astrocytoma Overview - Therapeutics Development - Pipeline Products for Anaplastic Astrocytoma - Overview - Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis - Anaplastic Astrocytoma - Therapeutics under Development by Companies - Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes - Anaplastic Astrocytoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Anaplastic Astrocytoma - Products under Development by Companies - Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes - Anaplastic Astrocytoma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Amgen Inc. - Axelar AB - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - Celldex Therapeutics, Inc. - e-Therapeutics Plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/mp9hzf/anaplastic
ADRO: 14.68 (-0.24), PFE: 36.89 (+0.22), CLDX: 4.62 (-0.10), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), NVS: 83.26 (+1.18)
A Look at Four Brain Cancer Companies for 2016
ACCESSWIRE - Mon Jan 04, 10:34AM CST
NEW YORK, NY / ACCESSWIRE / January 4, 2016 / BioTechstocks.com - Brain tumors are among the most difficult to treat cancers in the oncology space. Their tendency for late stage diagnosis, and the difficulty associated with surgical treatment, translates to a higher than 65% mortality rate in the US, defined as the percentage of patients that die within five years of diagnosis. Choosing to pursue brain cancer treatment is risky for a company precisely because it is so hard to treat. That's why new approaches are being pursued mainly by smaller companies trying to make an impact with bigger risk-taking. Here are four candidates from these smaller firms to keep in eye in 2016.
DMPI: 6.58 (-0.32), VBLT: 4.02 (unch), IMUC: 0.19 (-0.01)
Burzynski Research Institute, Inc. Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1
BusinessWire - Mon Dec 07, 12:42PM CST
Burzynski Research Institute, Inc. (BRI) announced today the publication of "A Phase II Study of Antineoplastons A10 and AS2-1 (ANP) in Adult Patients with Primary Brain Tumors - Final Report (Protocol BT-09)". This single arm, two stage, phase II clinical trial, was designed to treat adults with different types of primary brain tumors that were not curable by standard therapy. Fourteen of 40 patients treated (35%) had an anaplastic glioma (AG), of which 12 (86%) had an anaplastic astrocytoma (AA), a grade 3 tumor with a poor prognosis. In BT-09, the objective response rate in AA patients was 42% while the median progression-free survival was 5.4 months. The median overall survival (OS) for AA patients was 25.4 months with the OS at 6 months, 1 year, and 2 years being 83%, 58%, and 50% respectively, which compares favorably with current standard treatment. ANP was well-tolerated with reversible grade 3 and 4 toxicity in 35% of all 40 patients treated. After a review of BRI's Investigator Brochure and annual reports, which documented outcomes for all AGs treated with ANP in phase II clinical trials, the FDA, in personal correspondence with BRI, advised an end-of-phase II meeting "for grade 3 AGs, specifically AA, anaplastic oligodendroglioma, and mixed oligoastrocytoma [OR rate of 20% (95% CI: 12, 31)]", indicating that ANP exhibited sufficient clinical activity in these tumors to justify further development.
Burzynski Research Institute, Inc. Announces Publications Documenting Long-term Survival in Malignant Brain Tumors Following Antineoplaston Therapy
PR Newswire - Mon Oct 26, 5:03PM CDT
Burzynski Research Institute, Inc. (BRI) announced today the publication of two articles in the peer-reviewed literature that document long-term survival in patients with a high-grade glioma (HGG) following Antineoplaston therapy (ANP). Following standard therapy, HGGs have a very poor prognosis. A meta-analysis of 575 HGG studies involving 42,332 patients showed median overall survival ranging from 9.89 to 15.45 months depending on the type of adjuvant chemotherapy employed [Leonard A, et al. J. Neuro Oncol 2012 Jun; 14(Suppl 1): 156-168. doi: 10.1093/neuonc/nos12].
Gliosarcoma Pipeline Review H1 2015 - Analysis of 7 Companies & 11 Drug Profiles
M2 - Tue Jul 28, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mmkt6/gliosarcoma) has announced the addition of the "Gliosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Burzynski Research Institute, Inc. - Celgene Corporation - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Sanofi Drug Profiles - alisertib - Antineoplaston Therapy - CC-122 - DNX-2401 - indoximod - lonafarnib - Oncolytic Virus to Target IL-12 for Oncology - plerixafor - rilotumumab - SGT-53 - Stem Cell Therapy for Glioma For more information visit http://www.researchandmarkets.com/research/5m...liosarcoma
MRK: 58.66 (+0.23), NLNK: 10.58 (-0.53), AMGN: 172.03 (+0.75), CELGZ: 1.16 (-0.01)
Anaplastic Astrocytoma - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv742d/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amgen Inc. - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - e-Therapeutics plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncovir, Inc. - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/cv742d/anaplastic
PFE: 36.89 (+0.22), AMGN: 172.03 (+0.75), LLY: 82.89 (-0.04), NVS: 83.26 (+1.18)
Anaplastic Astrocytoma Therapeutic Products and Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 18, 8:30PM CDT
The report "Anaplastic Astrocytoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Anaplastic Astrocytoma with 33 market data tables and 14 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/anaplastic-a...eport.html .
PFE: 36.89 (+0.22), LLY: 82.89 (-0.04), NVS: 83.26 (+1.18)
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma
BusinessWire - Thu Jun 18, 2:09PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Patients with Non-Diffuse Intrinsic Pontine Glioma
BusinessWire - Thu Apr 16, 5:46PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain and brainstem tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma
BusinessWire - Tue Mar 31, 4:25PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with rare brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver
PR Newswire - Thu Mar 26, 5:51PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver.
Burzynski Research Institute awarded US FDA's approval to begin new clinical trial in Diffuse Intrinsic Brainstem Glioma
M2 - Mon Oct 27, 6:20AM CDT
Biopharmaceutical company Burzynski Research Institute (Other OTC:BZYR) revealed on Friday that it has received approval from the US Food and Drug Administration (FDA) to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > three months of age with a diffuse intrinsic brainstem glioma (DIPG), the most common brainstem tumor in children.
